We can all suffer from pain occasionally, and it’s never pleasant. Whether its toothache, period pain or back ache, we understand that discomfort can appear suddenly or be long-term and recurring.
CANTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the ...
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of ...
Reported positive YTD 2024 Adjusted EBITDA of $1.4 millionCompany expects Q4 2024 Net Revenue in the range of $37 million - $43 millionZYNRELEF® (bupivacaine and meloxicam) extended-release solution ...
The CrossLink partnership roll out, FDA approval of the VAN in September, and inclusion in the CMS Final Rule Non-Opioid Policy for Pain Relief, positions ZYNRELEF for significant growth ... open ...